KIF4A Promotes Glioblastoma Malignant Progression and Transmission of Temozolomide Resistance in the Tumor Microenvironment via the HIF1A/VEGFA Axis.

ABSTRACT:

Background

Glioblastoma (GBM) represents the most prevalent primary malignant brain tumor. Temozolomide (TMZ) is the primary chemotherapeutic agent administered following surgical resection. However, the emergence of TMZ resistance in patients undergoing chemotherapy significantly diminishes its efficacy. To date, the majority of preclinical studies have been unsuccessful in effectively overcoming TMZ resistance. Prior research has suggested that the KIF4A gene may serve as a prognostic indicator for patients with GBM. Nevertheless, the precise mechanism by which KIF4A contributes to TMZ resistance remains to be elucidated.

Methods

In order to simulate the in vivo growth environment of glioblastoma, transwell co-culture and hypoxia induction were employed. Functional experim

SUBMITTER: Shen X 

PROVIDER: S-EPMC12518161 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature